Stock Research for ALIM

ALIM

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ALIM Stock Chart & Research Data

The ALIM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALIM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ALIM Due diligence Resources & Stock Charts

The ALIM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALIM Detailed Price Forecast - CNN Money CNN View ALIM Detailed Summary - Google Finance
Yahoo View ALIM Detailed Summary - Yahoo! Finance Zacks View ALIM Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ALIM Trends & Analysis - Trade-Ideas Barrons View ALIM Major Holders - Barrons
NASDAQ View ALIM Call Transcripts - NASDAQ Seeking View ALIM Breaking News & Analysis - Seeking Alpha
Spotlight View ALIM Annual Report - CompanySpotlight.com OTC Report View ALIM OTC Short Report - OTCShortReport.com
TradeKing View ALIM Fundamentals - TradeKing Charts View ALIM SEC Filings - Bar Chart
WSJ View Historical Prices for ALIM - The WSJ Morningstar View Performance/Total Return for ALIM - Morningstar
MarketWatch View the Analyst Estimates for ALIM - MarketWatch CNBC View the Earnings History for ALIM - CNBC
StockMarketWatch View the ALIM Earnings - StockMarketWatch MacroAxis View ALIM Buy or Sell Recommendations - MacroAxis
Bullish View the ALIM Bullish Patterns - American Bulls Short Pains View ALIM Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ALIM Stock Mentions - StockTwits PennyStocks View ALIM Stock Mentions - PennyStockTweets
Twitter View ALIM Stock Mentions - Twitter Invest Hub View ALIM Investment Forum News - Investor Hub
Yahoo View ALIM Stock Mentions - Yahoo! Message Board Seeking Alpha View ALIM Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ALIM - SECform4.com Insider Cow View Insider Transactions for ALIM - Insider Cow
CNBC View ALIM Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALIM - OTC Markets
Yahoo View Insider Transactions for ALIM - Yahoo! Finance NASDAQ View Institutional Holdings for ALIM - NASDAQ


Stock Charts

FinViz View ALIM Stock Insight & Charts - FinViz.com StockCharts View ALIM Investment Charts - StockCharts.com
BarChart View ALIM Stock Overview & Charts - BarChart Trading View View ALIM User Generated Charts - Trading View




Latest Financial News for ALIM


Alimera Sciences Affirms Record 2018 Revenues
Posted on Monday January 07, 2019

ATLANTA, GA / ACCESSWIRE / January 7, 2019 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today affirmed that it expects record annual 2018 and fourth quarter 2018 revenues, with 2018 GAAP net revenue in excess of $45 million and fourth quarter 2018 GAAP net revenue in excess of $13 million. Additionally, Alimera anticipates reporting positive adjusted EBITDA for the three months ended December 31, 2018. In making this announcement, Alimera confirmed the previous estimates in its Current Report on Form 8-K dated December 4, 2018.


What Type Of Shareholder Owns Alimera Sciences, Inc.’s (NASDAQ:ALIM)?
Posted on Friday December 21, 2018

A look at the shareholders of Alimera Sciences, Inc. (NASDAQ:ALIM) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...


Alimera Sciences Announces Pricing Approval For ILUVIEN(R) in the U.A.E.
Posted on Monday December 17, 2018

ATLANTA, GA / ACCESSWIRE / December 17, 2018 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that pricing approval had been received for ILUVIEN from the United Arab Emirates Ministry of Health & Prevention, effective January 24, 2019 through its partner MEAgate International FZLLC, headquartered in Dubai. "Diabetes is an important disorder in our region with a high prevalence and lower levels of control by patients of their disease," said Dr. Ahmed ElBarky, Assistant Professor of Opthalmology, Benha University, Egypt, consultant vitreoretinal surgeon, Sheikh Khalifa Medical Center in Abu Dhabi. "We are glad that ILUVIEN, which represents the latest medical introduction and innovation in the treatment of DME, is now available for our patients.


Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer
Posted on Thursday November 29, 2018

ATLANTA, GA / ACCESSWIRE / November 29, 2018 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the company's Board of Directors has appointed Rick Eiswirth as Chief Executive Officer, effective January 2, 2019. Mr. Eiswirth will assume day-to-day leadership of the company, retain his title of President, and join Alimera's Board of Directors.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.